Confo Therapeutics announces exclusive, worldwide license agreement with VIB for Powerful Novel Structure Determination Technology
- Confo Therapeutics secures exclusive, worldwide license to new proprietary Megabody technology for GPCRs
- Megabody scaffold extends the utility of Confo® bodies to cryo-EM, without affecting their conformation selectivity
- Two Megabody publications in this week's issue of Nature reveal unprecedented high-resolution structure of the GABAA receptor
Ghent, Belgium: 3 January 2019 - Confo Therapeutics, an emerging drug discovery company, today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB's ‘Megabody' technology.
Megabodies are novel antigen-binding chimeric proteins which are ideally suited for three-dimensional structural analysis of proteins via high-resolution cryo-electron microscopy (cryo-EM).
The Megabody technology enabled an international team of scientists, including Confo Therapeutics' founder, Prof Jan Steyaert of the VIB-VUB Center for Structural Biology, to produce high resolution cryo-EM structures of the native human GABAA receptor in complex with common drugs for the first time - published in this week's Nature, see full references below.
More info on Confo Therapeutics' website
Next > Capricorn ICT Arkiv, Quest for Growth and Pamica invest in Leuven-based scale-up miaa Guard
Previous > iSTAR Medical’s MINIject maintains exceptional results in first-in-human trial one year post-surgery (STAR-I)